Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment

The therapeutic landscape for prostate cancer has expanded rapidly over recent years, marked by a paradigm shift toward earlier intervention, precision oncology, and biomarker-guided treatment in hormone-sensitive prostate cancer (HSPC). Clinicians are increasingly moving away from single-agent androgen deprivation therapy (ADT) or standard doublets, transitioning toward triplet combinations tailored to both tumor genomics and individual germline alterations. Along with established modalities including conventional ADT, docetaxel chemotherapy, and androgen receptor pathway inhibitors (ARPIs) like enzalutamide (Xtandi), apalutamide (Erleada), abiraterone (Zytiga), and darolutamide (Nubeqa), a rapid succession of clinical trial approvals through mid-2026 has significantly broadened frontline treatment choices.

Over the past year alone, 4 major clinical trials have redefined frontline HSPC management. ARANOTE (NCT02799602) validated a non-chemotherapy doublet combining darolutamide with ADT, resolving a gap where this regimen had not been as an ARPI-based approach without requiring docetaxel.

AMPLITUDE (NCT04497844) shifted PARP inhibition into the frontline HSPC setting, evaluating a quadruplet regimen of niraparib (Zejula), abiraterone, prednisone, and ADT for patients harboring germline or somatic BRCA mutations.

CAPitello-281 (NCT04493853) established PTEN deficiency as an actionable frontline biomarker, supporting the combination of the AKT inhibitor capivasertib (Truqap) with abiraterone, prednisone, and ADT, and reinforcing the necessity of early PTEN testing.

PSMAddition (NCT04720157)delivered the milestone July 2026 approval of Lutetium-177 (Pluvicto), advancing targeted radioligand therapy directly into the HSPC space after prior approval in the castration-resistant setting.

With major approvals emerging every few months, the management of HSPC is becoming highly individualized. By integrating genetic testing, biomarker screening, and target-directed agents early in the disease course, care teams can deploy personalized, highly potent combinations that maximize clinical outcomes while optimizing patient care strategies.